Literature DB >> 27701038

Analysis of fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics.

Hwang Eui Cho1, H Kang Min2.   

Abstract

A simple and accurate high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for the determination of N-(4-hydroxyphenyl)retinamide (fenretinide, 4-HPR) and its metabolites, 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) and N-(4-methoxyphenyl)retinamide (4-MPR), in human plasma. Plasma samples were prepared using protein precipitation with ethanol. Chromatographic separation of the three analytes and N-(4-ethoxyphenyl)retinamide (4-EPR), an internal standard, was achieved on a Zorbax SB-C18 column (3.5μm, 50×2.1mm) using gradient elution with the mobile phase of 0.1% formic acid in water and acetonitrile (pH* 2.4) at a flow rate of 0.5mL/min. Electrospray ionization (ESI) mass spectrometry was operated in the positive ion mode with multiple reaction monitoring (MRM). The calibration curves obtained were linear over the concentration range of 0.2-50ng/mL with a lower limit of quantification of 0.2ng/mL. The relative standard deviation of intra-day and inter-day precision was below 7.64%, and the accuracy ranged from 94.92 to 105.43%. The extraction recoveries were found to be higher than 90.39% and no matrix effect was observed. The analytes were stable for the durations of the stability studies. The validated method was successfully applied to the analyses of the pharmacokinetic study for patients treated with 4-HPR in a clinical trial.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Assay development; Clinical pharmacokinetics; Fenretinide (4-HPR); LC–MS/MS

Mesh:

Substances:

Year:  2016        PMID: 27701038      PMCID: PMC5231410          DOI: 10.1016/j.jpba.2016.09.046

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  29 in total

1.  Simple high-performance liquid chromatographic method for the separation of retinoids including N-(4-hydroxyphenyl)-all-trans-retinamide.

Authors:  T A Hultin; R G Mehta; R C Moon
Journal:  J Chromatogr       Date:  1985-05-31

2.  N-(4-hydroxyphenyl) retinamide induces cell cycle specific growth inhibition in PC3 cells.

Authors:  M Igawa; T Tanabe; G W Chodak; D B Rukstalis
Journal:  Prostate       Date:  1994-06       Impact factor: 4.104

3.  Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results.

Authors:  Fausto Chiesa; Nicoletta Tradati; Roberto Grigolato; Patrizia Boracchi; Elia Biganzoli; Nadia Crose; Elena Cavadini; Franca Formelli; Luigi Costa; Roberto Giardini; Stefano Zurrida; Alberto Costa; Giuseppe De Palo; Umberto Veronesi
Journal:  Int J Cancer       Date:  2005-07-01       Impact factor: 7.396

4.  Development of PLGA-based injectable delivery systems for hydrophobic fenretinide.

Authors:  Christian Wischke; Ying Zhang; Sachin Mittal; Steven P Schwendeman
Journal:  Pharm Res       Date:  2010-07-29       Impact factor: 4.200

5.  Identification of the fenretinide metabolite 4-oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1.

Authors:  Maria Grazia Villani; Valentina Appierto; Elena Cavadini; Manuela Valsecchi; Sandro Sonnino; Robert W Curley; Franca Formelli
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

6.  Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.

Authors:  Anita L Sabichi; Manual R Modiano; J Jack Lee; Yei-Mei Peng; Ming-Jing Xu; Hugo Villar; William S Dalton; Scott M Lippman
Journal:  Clin Cancer Res       Date:  2003-07       Impact factor: 12.531

7.  Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer.

Authors:  Anita L Sabichi; Seth P Lerner; E Neely Atkinson; H Barton Grossman; Nancy P Caraway; Colin P Dinney; David F Penson; Surena Matin; Ashish Kamat; Louis L Pisters; Daniel W Lin; Ruth L Katz; Dean E Brenner; George P Hemstreet; Mary Wargo; Archie Bleyer; William H Sanders; John L Clifford; Howard L Parnes; Scott M Lippman
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

8.  The effect of tamoxifen and fenretinimide on human colorectal cancer cell lines in vitro.

Authors:  Y Ziv; M K Gupta; J W Milsom; A Vladisavljevic; M Brand; V W Fazio
Journal:  Anticancer Res       Date:  1994 Sep-Oct       Impact factor: 2.480

9.  N-(4-hydroxyphenyl)retinamide: interactions with retinoid-binding proteins/receptors.

Authors:  B P Sani; Y F Shealy; D L Hill
Journal:  Carcinogenesis       Date:  1995-10       Impact factor: 4.944

10.  Distribution and metabolism of the retinoid, N-(4-methoxyphenyl)-all-trans-retinamide, the major metabolite of N-(4-hydroxyphenyl)-all-trans-retinamide, in female mice.

Authors:  T A Hultin; M S Filla; D L McCormick
Journal:  Drug Metab Dispos       Date:  1990 Mar-Apr       Impact factor: 3.922

View more
  3 in total

1.  One-Step, Low-Cost, Operator-Friendly, and Scalable Procedure to Synthetize Highly Pure N-(4-ethoxyphenyl)-retinamide in Quantitative Yield without Purification Work-Up.

Authors:  Silvana Alfei; Guendalina Zuccari
Journal:  Molecules       Date:  2022-06-06       Impact factor: 4.927

2.  Hydrophilic interaction liquid chromatography-tandem mass spectrometric approach for simultaneous determination of safingol and D-erythro-sphinganine in human plasma.

Authors:  Hwang Eui Cho; Barry J Maurer; C Patrick Reynolds; Min H Kang
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2019-02-22       Impact factor: 3.205

3.  A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors.

Authors:  Jacob S Thomas; Anthony B El-Khoueiry; Barry J Maurer; Susan Groshen; Jacek K Pinski; Everardo Cobos; David R Gandara; Heinz J Lenz; Min H Kang; C Patrick Reynolds; Edward M Newman
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-10       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.